Enzalutamide in chemotherapy-naive mCRPC

Enzalutamide improved overall survival and radiographic progression-free survival in patients with chemotherapy-naive metastatic castration-resistant prostate cancer in the randomised, double-blind, placebo-controlled, multinational, phase III PREVAIL study. The study findings were presented as abstract LBA1 in the Welcome and General Session entitled “Integrating Androgen Axis Therapy Across the Disease Spectrum” of the 2014 Genitourinary Cancer Symposium in San Francisco. Read more here.